B

Boundless Bio Inc
NASDAQ:BOLD

Watchlist Manager
Boundless Bio Inc
NASDAQ:BOLD
Watchlist
Price: 3.32 USD -7% Market Closed
Market Cap: 73.9m USD
Have any thoughts about
Boundless Bio Inc?
Write Note

Intrinsic Value

BOLD's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one BOLD stock under the Base Case scenario is 5.43 USD. Compared to the current market price of 3.32 USD, Boundless Bio Inc is Undervalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BOLD Intrinsic Value
5.43 USD
Undervaluation 39%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Boundless Bio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BOLD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BOLD?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Boundless Bio Inc

Provide an overview of the primary business activities
of Boundless Bio Inc.

What unique competitive advantages
does Boundless Bio Inc hold over its rivals?

What risks and challenges
does Boundless Bio Inc face in the near future?

Summarize the latest earnings call
of Boundless Bio Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Boundless Bio Inc.

Provide P/S
for Boundless Bio Inc.

Provide P/E
for Boundless Bio Inc.

Provide P/OCF
for Boundless Bio Inc.

Provide P/FCFE
for Boundless Bio Inc.

Provide P/B
for Boundless Bio Inc.

Provide EV/S
for Boundless Bio Inc.

Provide EV/GP
for Boundless Bio Inc.

Provide EV/EBITDA
for Boundless Bio Inc.

Provide EV/EBIT
for Boundless Bio Inc.

Provide EV/OCF
for Boundless Bio Inc.

Provide EV/FCFF
for Boundless Bio Inc.

Provide EV/IC
for Boundless Bio Inc.

Show me price targets
for Boundless Bio Inc made by professional analysts.

What are the Revenue projections
for Boundless Bio Inc?

How accurate were the past Revenue estimates
for Boundless Bio Inc?

What are the Net Income projections
for Boundless Bio Inc?

How accurate were the past Net Income estimates
for Boundless Bio Inc?

What are the EPS projections
for Boundless Bio Inc?

How accurate were the past EPS estimates
for Boundless Bio Inc?

What are the EBIT projections
for Boundless Bio Inc?

How accurate were the past EBIT estimates
for Boundless Bio Inc?

Compare the revenue forecasts
for Boundless Bio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Boundless Bio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Boundless Bio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Boundless Bio Inc compared to its peers.

Compare the P/E ratios
of Boundless Bio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Boundless Bio Inc with its peers.

Analyze the financial leverage
of Boundless Bio Inc compared to its main competitors.

Show all profitability ratios
for Boundless Bio Inc.

Provide ROE
for Boundless Bio Inc.

Provide ROA
for Boundless Bio Inc.

Provide ROIC
for Boundless Bio Inc.

Provide ROCE
for Boundless Bio Inc.

Provide Gross Margin
for Boundless Bio Inc.

Provide Operating Margin
for Boundless Bio Inc.

Provide Net Margin
for Boundless Bio Inc.

Provide FCF Margin
for Boundless Bio Inc.

Show all solvency ratios
for Boundless Bio Inc.

Provide D/E Ratio
for Boundless Bio Inc.

Provide D/A Ratio
for Boundless Bio Inc.

Provide Interest Coverage Ratio
for Boundless Bio Inc.

Provide Altman Z-Score Ratio
for Boundless Bio Inc.

Provide Quick Ratio
for Boundless Bio Inc.

Provide Current Ratio
for Boundless Bio Inc.

Provide Cash Ratio
for Boundless Bio Inc.

What is the historical Revenue growth
over the last 5 years for Boundless Bio Inc?

What is the historical Net Income growth
over the last 5 years for Boundless Bio Inc?

What is the current Free Cash Flow
of Boundless Bio Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Boundless Bio Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Boundless Bio Inc

Balance Sheet Decomposition
Boundless Bio Inc

Current Assets 183.1m
Cash & Short-Term Investments 179.3m
Other Current Assets 3.8m
Non-Current Assets 5.1m
PP&E 4.5m
Other Non-Current Assets 578k
Current Liabilities 9m
Accounts Payable 1.7m
Accrued Liabilities 7.3m
Efficiency

Earnings Waterfall
Boundless Bio Inc

Revenue
0 USD
Operating Expenses
-65m USD
Operating Income
-65m USD
Other Expenses
7.3m USD
Net Income
-57.7m USD

Free Cash Flow Analysis
Boundless Bio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BOLD Profitability Score
Profitability Due Diligence

Boundless Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Boundless Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BOLD Solvency Score
Solvency Due Diligence

Boundless Bio Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
74/100
Solvency
Score

Boundless Bio Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BOLD Price Targets Summary
Boundless Bio Inc

Wall Street analysts forecast BOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BOLD is 20.06 USD with a low forecast of 14.14 USD and a high forecast of 25.2 USD.

Lowest
Price Target
14.14 USD
326% Upside
Average
Price Target
20.06 USD
504% Upside
Highest
Price Target
25.2 USD
659% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BOLD?

Click here to dive deeper.

Dividends

Boundless Bio Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BOLD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Boundless Bio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

73.9m USD

Dividend Yield

0%

Description

Boundless Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 71 full-time employees. The company went IPO on 2024-03-28. Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.

Contact

CALIFORNIA
San Diego
9880 Campus Point Drive, Suite 120
+18587669912
boundlessbio.com

IPO

2024-03-28

Employees

71

Officers

Co-Founder & Independent Chairman
Dr. Jonathan E. Lim M.D.
CEO, President & Director
Mr. Zachary Hornby
Chief Scientific Officer
Dr. Christian Hassig Ph.D.
Chief Medical Officer
Dr. Klaus W. Wagner M.D., Ph.D.
Senior VP of Finance & Controller
Mr. David Hinkle
Chief Legal Officer & Corporate Secretary
Ms. Jessica Oien J.D.
Show More
Chief Business Officer
Mr. Neil Abdollahian M.B.A., M.S.
Senior Vice President of Drug Discovery
Mr. Anthony Pinkerton Ph.D.
Senior Vice President of Talent & Culture
Ms. Meredith Wesley
Senior Vice President of Discovery & Translational Development
Dr. Shailaja Kasibhatla Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BOLD stock?

The intrinsic value of one BOLD stock under the Base Case scenario is 5.43 USD.

Is BOLD stock undervalued or overvalued?

Compared to the current market price of 3.32 USD, Boundless Bio Inc is Undervalued by 39%.

Back to Top